Category: Cervical Cancer / HPV Vaccine

Gen-Probe’s (Nasdaq: GPRO) CE-marked APTIMA(R) HPV assay may be an important new molecular tool to more accurately detect high-risk human papillomavirus (HPV) infections that are associated with cervical cancer or precancerous lesions, according to nine oral presentations and two scie

Share and Enjoy:
These icons […]

While officials in the United Kingdom and the U.S. are “dithering and doubting” over issues related to GlaxoSmithKline and Merck’s HPV vaccines, “there is an urgent need” for Gardasil and Cervarix in developing countries, Sarah Boseley — health editor at London’s

Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover […]

Physicians in the U.S. are reporting a higher risk for certain types of cancers — such as liver, head, neck and lung — in people living with HIV/AIDS, raising concerns that a cancer epidemic is imminent in the population, the Baltimore Sun reports. According to the Sun, Meredith Shiels, a doctoral candidate at the

Share and […]

In a campaign to significantly reduce the most common cancer affecting Mexican women, the Mexican Public Health Agency (Secretaria de Salud) announced that it is launching the first phase of a program that will offer free testing for human papillomavirus (HPV), the primary cause of cervical cancer, to all low-income women age 35-65.

Share and Enjoy:
These […]

The Treatment Action Campaign of South Africa is calling on pharmaceutical companies to “dramatically lower the prices” of human papillomavirus vaccines to make them more affordable for HIV-positive women, the Cape Times/IOL reports.

Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.

Latest results from a clinical trial of Gardisal™, the Australian developed vaccine for human papilloma virus, add to the growing weight of opinion that the Government should extend its funding of the vaccine to boys. The research was presented today (18/11) to the Clinical Oncolgoical Society of Australia Annual Scientific Meeting in Sydney.

Share and Enjoy:
These […]

The four-type (6,11,16,18) human papillomavirus (HPV) vaccine Gardasil® is also effective in men according to the primary analysis from a pivotal phase III clinical study. In previously uninfected men aged 16 to 26 years*, Gardasil® prevented 90% (95%CI: 69, 98) of external genital lesions caused by HPV types 6, […]

Information about vaccination against the virus that causes cervical cancer could encourage rather than discourage women to attend for cervical screening, a new survey has found.1 A number of commentators have said that vaccinating women against the human papillomavirus (HPV), which causes cervical cancer, could make them complacent about attending for cervical […]

Arbor Vita Corporation (AVC), a privately held biopharmaceutical company, presented new data on its rapid, point-of-care prototype HPV test with a high positive predictive value for cervical cancer and pre-cancer. Targeted for use throughout the developing world, this diagnostic test is being developed in partnership with PATH.

Share and Enjoy:
These icons link to social bookmarking sites […]

GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent of external genital lesions caused by human papillomavirus (HPV) types 6, 11, 16 and 18 in a pivotal Phase III study in men aged 16 to 26.

Share and Enjoy:
These icons link […]